About Vascular Solutions (NASDAQ:VASC)
Vascular Solutions, Inc. is a medical device company focused on bringing clinically advanced solutions to the market for treating coronary and peripheral vascular disease. The Company's product line consists of devices and services that are sold to interventional cardiologists, interventional radiologists, electrophysiologists and vein practices around the world. Its products include GuideLiner catheters, Pronto catheters, Vein catheter reprocessing, Micro-introducer kits, Hemostatic patches, Radial access products, Langston catheters and D-Stat Flowable hemostat. The Company's product portfolio includes a spectrum of over 90 products consisting of approximately 900 stock keeping units (SKUs) covering an array of blood clotting devices, extraction catheters, access catheters, guide extension catheters, micro-introducer kits, guidewires, snare and retrieval devices, a reprocessing service for radiofrequency catheters and a laser and procedure kits for the treatment of varicose veins.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryHealth Care Supplies
SectorN/A
SymbolNASDAQ:VASC
CUSIP92231M10
Phone+1-763-6564300
Debt
Debt-to-Equity RatioN/A
Current Ratio6.37%
Quick Ratio4.66%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net Margins13.02%
Return on Equity15.78%
Return on Assets14.30%
Miscellaneous
Employees568
Outstanding Shares17,570,000
Vascular Solutions (NASDAQ:VASC) Frequently Asked Questions
What is Vascular Solutions' stock symbol?
Vascular Solutions trades on the NASDAQ under the ticker symbol "VASC."
How were Vascular Solutions' earnings last quarter?
Vascular Solutions, Inc. (NASDAQ:VASC) announced its earnings results on Monday, July, 25th. The medical device company reported $0.33 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.30 by $0.03. The medical device company had revenue of $41.20 million for the quarter, compared to analyst estimates of $41.40 million. Vascular Solutions had a return on equity of 15.78% and a net margin of 13.02%. Vascular Solutions's revenue for the quarter was up 9.7% compared to the same quarter last year. During the same quarter last year, the firm earned $0.29 EPS. View Vascular Solutions' Earnings History.
Has Vascular Solutions been receiving favorable news coverage?
News articles about VASC stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Vascular Solutions earned a media sentiment score of 0.20 on Accern's scale. They also assigned news headlines about the medical device company an impact score of 47.26 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company's share price in the next few days.
How do I buy shares of Vascular Solutions?
Shares of VASC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vascular Solutions' stock price today?
One share of VASC stock can currently be purchased for approximately $56.00.
How can I contact Vascular Solutions?
Vascular Solutions' mailing address is 6464 Sycamore Ct N, MAPLE GROVE, MN 55369-6032, United States. The medical device company can be reached via phone at +1-763-6564300.
MarketBeat Community Rating for Vascular Solutions (VASC)
MarketBeat's community ratings are surveys of what our community members think about Vascular Solutions and other stocks. Vote "Outperform" if you believe VASC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VASC will underperform the S&P 500 over the long term. You may vote once every thirty days.
Vascular Solutions (NASDAQ:VASC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | N/A | N/A | N/A | Hold |
| Consensus Rating Score: | N/A | N/A | N/A | 2.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | N/A | N/A | N/A | $58.00 |
| Price Target Upside: | N/A | N/A | N/A | 3.57% upside |
Vascular Solutions (NASDAQ:VASC) Consensus Price Target History
Vascular Solutions (NASDAQ:VASC) Analyst Ratings History
Show:
(Data available from 4/24/2016 forward)
Vascular Solutions (NASDAQ:VASC) Earnings History and Estimates Chart
Vascular Solutions (NASDAQ VASC) Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 10/24/2016 | Q3 | $0.30 | $0.31 | $41.60 million | $41.77 million | View | Listen |  |
| 7/25/2016 | Q216 | $0.30 | $0.33 | $41.40 million | $41.20 million | View | Listen | |
| 4/25/2016 | Q116 | $0.23 | $0.25 | $38.37 million | $39.00 million | View | Listen | |
| 1/21/2016 | Q415 | $0.27 | $0.33 | $37.53 million | $38.09 million | View | Listen | |
| 10/20/2015 | Q315 | $0.25 | $0.27 | $36.41 million | $37.00 million | View | Listen | |
| 7/21/2015 | Q215 | $0.25 | $0.29 | $35.59 million | $37.60 million | View | Listen | |
| 4/21/2015 | Q115 | $0.18 | $0.21 | $33.38 million | $34.61 million | View | N/A | |
| 2/3/2015 | Q414 | $0.18 | $0.23 | $32.82 million | $33.60 million | View | N/A | |
| 10/21/2014 | Q314 | $0.20 | $0.15 | $31.10 million | $31.90 million | View | Listen | |
| 7/22/2014 | Q214 | $0.18 | $0.20 | $30.43 million | $30.70 million | View | N/A | |
| 4/22/2014 | Q114 | $0.18 | $0.16 | $29.91 million | $29.91 million | View | Listen | |
| 2/4/2014 | Q413 | $0.19 | $0.22 | $28.61 million | $29.10 million | View | Listen | |
| 10/22/2013 | Q313 | $0.07 | $0.19 | $27.10 million | $28.01 million | View | Listen | |
| 7/23/2013 | Q2 2013 | $0.17 | $0.17 | $27.00 million | $27.40 million | View | N/A | |
| 4/23/2013 | Q1 2013 | $0.15 | $0.16 | $26.51 million | $26.10 million | View | Listen | |
| 2/5/2013 | Q4 2012 | $0.17 | $0.18 | $25.59 million | $25.30 million | View | Listen | |
| 10/18/2012 | | $0.15 | $0.16 | | | View | N/A | |
| 7/24/2012 | | $0.13 | $0.15 | | | View | N/A | |
| 4/24/2012 | Q1 2012 | $0.11 | $0.12 | | | View | N/A | |
| 2/1/2012 | | $0.13 | $0.13 | | | View | N/A | |
| 10/25/2011 | | $0.17 | $0.10 | | | View | N/A | |
| 8/2/2011 | | $0.12 | $0.13 | | | View | N/A | |
| 4/19/2011 | | $0.10 | $0.10 | | | View | N/A | |
| 2/1/2011 | | $0.12 | $0.12 | | | View | N/A | |
| 10/20/2010 | Q3 2010 | $0.10 | $0.09 | | | View | N/A | |
| 7/22/2010 | Q2 2010 | $0.10 | $0.09 | | | View | N/A | |
| 4/20/2010 | Q1 2010 | $0.08 | $0.08 | | | View | N/A | |
| 2/2/2010 | Q4 2009 | $0.10 | $0.10 | | | View | N/A | |
| 10/20/2009 | Q3 2009 | $0.09 | $0.09 | | | View | N/A | |
| 7/22/2009 | Q2 2009 | $0.07 | $0.09 | | | View | N/A | |
| 4/16/2009 | Q1 2009 | $0.06 | $0.06 | | | View | N/A | |
| 2/3/2009 | Q4 2008 | $0.12 | $0.09 | | | View | N/A | |
| 10/21/2008 | Q3 2008 | $0.06 | $0.11 | | | View | N/A | |
| 7/23/2008 | Q2 2008 | $0.04 | $0.03 | | | View | N/A | |
| 4/17/2008 | Q1 2008 | $0.04 | $0.02 | | | View | N/A | |
| 2/4/2008 | Q4 2007 | $0.02 | $0.03 | | | View | N/A | |
(Earnings results data provided by Zacks Investment Research)
Vascular Solutions (NASDAQ:VASC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Vascular Solutions (NASDAQ VASC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 6.90%
Institutional Ownership Percentage: 80.18%
Vascular Solutions (NASDAQ VASC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 12/22/2016 | Chad Kugler | VP | Sell | 1,849 | $55.70 | $102,989.30 | | |
| 7/27/2016 | Howard Root | CEO | Sell | 40,000 | $45.11 | $1,804,400.00 | 347,840 | |
| 7/27/2016 | William Rutstein | VP | Sell | 10,011 | $46.26 | $463,108.86 | | |
| 5/24/2016 | Howard Root | CEO | Sell | 34,418 | $39.05 | $1,344,022.90 | 348,340 | |
| 5/13/2016 | James Hennen | CFO | Sell | 11,785 | $38.12 | $449,244.20 | 45,073 | |
| 5/13/2016 | Martin J Emerson | Director | Sell | 20,000 | $37.93 | $758,600.00 | 8,435 | |
| 4/28/2016 | John L Erb | Director | Sell | 10,000 | $35.58 | $355,800.00 | 10,306 | |
| 4/27/2016 | Howard Root | CEO | Sell | 15,582 | $36.07 | $562,042.74 | 351,340 | |
| 4/27/2016 | Timothy Slayton | Insider | Sell | 2,994 | $36.72 | $109,939.68 | 9,787 | |
| 2/29/2016 | Charmaine Sutton | VP | Sell | 14,325 | $30.13 | $431,612.25 | 72,717 | |
| 11/19/2015 | Jorge Saucedo | Director | Sell | 7,715 | $33.45 | $258,066.75 | 19,320 | |
| 11/4/2015 | Richard Nigon | Director | Sell | 8,000 | $32.40 | $259,200.00 | 57,008 | |
| 11/2/2015 | Howard Root | CEO | Sell | 18,062 | $32.03 | $578,525.86 | 344,349 | |
| 10/26/2015 | Carrie Powers | VP | Sell | 5,412 | $32.77 | $177,351.24 | 26,422 | |
| 8/20/2015 | Jorge Saucedo | Director | Sell | 2,285 | $38.00 | $86,830.00 | 27,035 | |
| 7/23/2015 | Timothy Slayton | Insider | Sell | 1,587 | $38.61 | $61,274.07 | | |
| 5/28/2015 | Richard Nigon | Director | Sell | 6,000 | $32.68 | $196,080.00 | | |
| 5/4/2015 | Howard Root | CEO | Sell | 25,000 | $32.62 | $815,500.00 | | |
| 4/27/2015 | Carrie Powers | VP | Sell | 6,000 | $34.90 | $209,400.00 | | |
| 4/24/2015 | James Hennen | CFO | Sell | 4,792 | $35.66 | $170,882.72 | | |
| 2/10/2015 | William Rutstein | VP | Sell | 10,814 | $26.91 | $291,004.74 | | |
| 2/5/2015 | James Hennen | CFO | Sell | 11,301 | $27.62 | $312,133.62 | | |
| 2/5/2015 | Jorge Saucedo | Director | Sell | 10,000 | $27.36 | $273,600.00 | | |
| 11/26/2014 | Richard Nigon | Director | Buy | 3,000 | $25.80 | $77,400.00 | | |
| 11/14/2014 | Richard W Kramp | Director | Buy | 1,475 | $23.69 | $34,942.75 | | |
| 4/24/2014 | Timothy Slayton | Insider | Sell | 1,390 | $23.15 | $32,178.50 | 9,265 | |
| 2/27/2014 | James Hennen | CFO | Sell | 10,000 | $25.42 | $254,200.00 | 50,151 | |
| 2/25/2014 | Howard Root | CEO | Sell | 50,000 | $24.74 | $1,237,000.00 | 445,990 | |
| 2/25/2014 | Richard Nigon | Director | Buy | 1,000 | $25.66 | $25,660.00 | 58,187 | |
| 2/14/2014 | Howard Root | CEO | Sell | 25,000 | $25.13 | $628,250.00 | 445,990 | |
| 2/11/2014 | Paul O'connell | Director | Sell | 2,000 | $24.43 | $48,860.00 | 4,687 | |
| 2/10/2014 | William Rutstein | VP | Sell | 27,782 | $23.80 | $661,211.60 | 38,425 | |
| 10/28/2013 | James Hennen | CFO | Sell | 10,000 | $19.72 | $197,200.00 | | |
| 10/25/2013 | Jorge Saucedo | Director | Sell | 2,000 | $19.70 | $39,400.00 | | |
| 7/26/2013 | Charmaine Sutton | VP | Sell | 7,538 | $16.15 | $121,738.70 | | |
| 7/25/2013 | Howard Root | CEO | Sell | 21,580 | $16.10 | $347,438.00 | | |
| 7/25/2013 | Howard Root | CEO | Sell | 21,580 | $16.10 | $347,438.00 | | |
| 7/25/2013 | Paul O'connell | Director | Sell | 30,000 | $16.11 | $483,300.00 | | |
| 5/17/2013 | Paul O'connell | Director | Sell | 10,000 | $16.05 | $160,500.00 | | |
| 5/1/2013 | Richard Nigon | Director | Buy | 3,000 | $15.57 | $46,710.00 | | |
| 11/26/2012 | Susan Christian | VP | Sell | 7,648 | $14.41 | $110,207.68 | | |
(Data available from 1/1/2013 forward)
Vascular Solutions (NASDAQ VASC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Global Cathers Market Competitive landscape: Vascular Solutions, Braun Melsungen AG
www.marketwatch.com - April 24 at 9:12 AM |
 | Bardy Diagnostics™ Recognized by MedTech Outlook as One of the Top 10 Cardio Vascular Device Companies of 2018
www.bizjournals.com - April 19 at 9:11 AM |
 | Velano Vascular Named 2018’s Gold Edison Award™ Winner
globenewswire.com - April 17 at 9:36 AM |
| Wolters Kluwer to Lead Healthcare Webinar Series with Libman Education
www.bizjournals.com - April 6 at 9:37 AM |
| Global Catheters Market Opportunities 2018: Vascular Solutions, Medtronic, Johnson &, Johnson, Abbott Laboratories
www.marketwatch.com - March 13 at 9:33 AM |
| 4C Medical's Novel Mitral Regurgitation Therapy to be Highlighted at CRT 2018 Meeting
www.bizjournals.com - March 2 at 9:08 AM |
| Global varicose vein treatment market expected to be driven by increasing adoption and benefits associated with varicose vein treatment
www.marketwatch.com - March 2 at 9:08 AM |
| Oramed Adds Two New Members to its Scientific Advisory Board
www.bizjournals.com - February 28 at 9:10 AM |
 | Penumbra (PEN) Forms JV on Virtual Reality in Health Space
www.zacks.com - January 5 at 4:01 PM |
 | Toshiba Medical Expands Customer Education Solutions with Interactive Learning Tools Designed for the Modern Learner
www.businesswire.com - November 28 at 4:21 PM |
| Urinary Catheters Market is Worth US$ 15830 Million By 2022
www.marketwatch.com - November 16 at 5:08 AM |
 | Teleflex (TFX) Q3 2017 Results - Earnings Call Transcript
seekingalpha.com - November 2 at 3:40 PM |
 | Vascular Solutions (VASC) & Myriad Genetics (MYGN) Critical Survey
www.americanbankingnews.com - September 9 at 2:12 AM |
| Analyzing VAREX IMAGING (VREX) and Vascular Solutions (VASC)
www.americanbankingnews.com - September 5 at 10:22 AM |
| Head-To-Head Analysis: Vascular Solutions (VASC) vs. Myriad Genetics (MYGN)
www.americanbankingnews.com - September 3 at 4:02 AM |
| Financial Comparison: Myriad Genetics (MYGN) vs. Vascular Solutions (VASC)
www.americanbankingnews.com - August 30 at 4:26 PM |
| Reviewing Vascular Solutions (VASC) & Myriad Genetics (MYGN)
www.americanbankingnews.com - August 29 at 8:06 PM |
| Comparing Vascular Solutions (VASC) and Cepheid (CPHD)
www.americanbankingnews.com - August 27 at 12:28 AM |
| Head-To-Head Comparison: Vascular Solutions (VASC) and Varex Imaging (VREX)
www.americanbankingnews.com - August 25 at 4:30 PM |
| Financial Analysis: Varex Imaging (VREX) & Vascular Solutions (VASC)
www.americanbankingnews.com - August 18 at 6:14 PM |
| Financial Contrast: Cepheid (CPHD) & Vascular Solutions (NASDAQ:VASC)
www.americanbankingnews.com - August 10 at 3:02 PM |
| Teleflex (TFX) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 4 at 9:37 AM |
| Vascular Solutions (VASC) versus Cepheid (CPHD) Head-To-Head Contrast
www.americanbankingnews.com - August 4 at 7:42 AM |
| Head to Head Survey: Vascular Solutions (VASC) & Sequenom (SQNM)
www.americanbankingnews.com - July 13 at 8:30 PM |
| Head to Head Survey: Oxford Immunotec Global PLC (OXFD) & Vascular Solutions (VASC)
www.americanbankingnews.com - July 1 at 8:12 AM |
 | BRIEF-Teleflex's (TFX) Vascular Solutions issues recall of venture catheters
www.reuters.com - June 22 at 7:31 PM |
| Teleflex’s (TFX) Vascular Solutions, Inc. Issues Recall of Venture ® Catheters
www.businesswire.com - June 22 at 7:31 PM |
| Teleflex to Introduce Arrow AC3 Optimus at EuroPCR, Paris
www.zacks.com - May 16 at 8:24 AM |
| Sunshine Heart Hires Gordon Weber as Vice President, General Counsel
globenewswire.com - May 16 at 8:24 AM |
 | Teleflex Lifts 2017 Profit View
www.nasdaq.com - May 4 at 9:49 AM |
 | 1:01 pm Index Changes Reminder: Progenics Pharmaceuticals (PGNX) replaced Calamos Asset (CLMS) in the S&P SmallCap 600 this morning; and Shutterfly (
us.rd.yahoo.com - February 23 at 3:06 AM |
 | VASCULAR SOLUTIONS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Completion of Acquisition
biz.yahoo.com - February 22 at 10:46 AM |
| VASCULAR SOLUTIONS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders, Other Events, Financi
biz.yahoo.com - February 17 at 5:57 AM |
| Vascular Solutions CEO Howard Root stands to receive $8M in sale of company
www.bizjournals.com - January 19 at 4:18 PM |
| INVESTOR ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular Solutions, Inc. And Encourages Shareholders To Contact The Firm For Additional ...
www.businesswire.com - December 18 at 4:04 AM |
| SHAREHOLDER ALERT: Brower Piven Commences An Investigation Into The Proposed Sale Of Vascular Solutions, Inc. And Encourages Investors To Contact The Firm For Additional ...
www.businesswire.com - December 14 at 8:19 AM |
| INVESTOR ALERT: Levi & Korsinsky, LLP Announces an Investigation Concerning Whether the Sale of Vascular Solutions, Inc. to Teleflex Incorporated for $24 Per Share is Fair to ...
www.businesswire.com - December 7 at 9:13 PM |
| Company News for December 05, 2016
us.rd.yahoo.com - December 5 at 3:56 PM |
| Ryan & Maniskas, LLP Announces Investigation of Vascular Solutions, Inc.
us.rd.yahoo.com - December 5 at 3:56 PM |
| VASCULAR SOLUTIONS, INC. SHAREHOLDER ALERT: Former SEC Attorney Willie Briscoe and Powers Taylor LLP Investigate Sale to Teleflex Incorporated
us.rd.yahoo.com - December 5 at 3:56 PM |
 | Medical device maker Teleflex to buy Vascular Solutions for $1 billion
www.foxnews.com - December 3 at 9:37 AM |
Vascular Solutions (NASDAQ:VASC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Vascular Solutions (NASDAQ:VASC) Income Statement, Balance Sheet and Cash Flow Statement
Vascular Solutions (NASDAQ VASC) Stock Chart for Tuesday, April, 24, 2018
Loading chart…
